Payment overview · 2025
General Payments
$748.62
42 reported records · 13 companies
Healthcare provider profile · identity verified
Donetta Wallace, P.A.-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · PAINTSVILLE, KY · NPI 1417958828
Verified facts
What the public records show
CMS Open Payments records show Donetta Wallace, P.A.-C received $748.62 in general payments during 2025 across 42 reported records.
Novo Nordisk Inc accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.43 | 21.8% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $150.21 | 20.1% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $100.15 | 13.4% | 6 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $66.76 | 8.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $57.26 | 7.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.28 | 6.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.83 | 4.1% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.96 | 3.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $27.19 | 3.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.42 | 3.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.67 | 2.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.50 | 1.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.96 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $748.62 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $138.25 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $138.25 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $134.58 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $100.15 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $97.24 | 5 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $66.76 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $57.26 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.28 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.01 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $25.42 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.18 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 46 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
107 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 487 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 393 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 329 | 114 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 329 | 117 |
| Lisinopril | Lisinopril | 298 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 262 | 79 |
| Gabapentin | Gabapentin | 260 | 39 |
| Omeprazole | Omeprazole | 232 | 85 |
| Furosemide | Furosemide | 221 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 217 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 63 |
| Metformin Hcl | Metformin Hcl | 202 | 56 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 200 | 67 |
| Famotidine | Famotidine | 184 | 69 |
| Duloxetine Hcl | Duloxetine Hcl | 180 | 38 |
| Cefdinir | Cefdinir | 168 | 125 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 45 |
| Tramadol Hcl | Tramadol Hcl | 166 | 33 |
| Potassium Chloride | Potassium Chloride | 161 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 56 |
| Diazepam | Diazepam | 157 | 27 |
| Glipizide Er | Glipizide | 148 | 43 |
| Montelukast Sodium | Montelukast Sodium | 147 | 47 |
| Losartan Potassium | Losartan Potassium | 146 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 38 |
| Valsartan | Valsartan | 132 | 35 |
| Jardiance | Empagliflozin | 124 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 124 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 122 | 83 |
| Simvastatin | Simvastatin | 120 | 37 |
| Trazodone Hcl | Trazodone Hcl | 116 | 36 |
| Eliquis | Apixaban | 113 | 33 |
| Fluconazole | Fluconazole | 108 | 61 |
| Sertraline Hcl | Sertraline Hcl | 108 | 35 |
| Linzess | Linaclotide | 107 | 33 |
| Carvedilol | Carvedilol | 104 | 33 |
| Ibuprofen | Ibuprofen | 99 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 20 |
| Nystatin | Nystatin | 93 | 54 |
| Buspirone Hcl | Buspirone Hcl | 92 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 91 | 66 |
| Ozempic | Semaglutide | 88 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 27 |
| Clonidine Hcl | Clonidine Hcl | 85 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 83 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 83 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 21 |
| Mounjaro | Tirzepatide | 79 | 17 |
| Methylprednisolone | Methylprednisolone | 78 | 63 |
| Allopurinol | Allopurinol | 76 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 21 |
| Alendronate Sodium | Alendronate Sodium | 73 | 24 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 70 | suppressed |
| Meloxicam | Meloxicam | 68 | 29 |
| Prednisone | Prednisone | 68 | 53 |
| Sucralfate | Sucralfate | 68 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 26 |
| Azithromycin | Azithromycin | 64 | 58 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 22 |
| Baclofen | Baclofen | 62 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 25 |
| Glipizide | Glipizide | 60 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 60 | 23 |
| Clonazepam | Clonazepam | 59 | 11 |
| Methocarbamol | Methocarbamol | 59 | 17 |
| Pregabalin | Pregabalin | 59 | 11 |
| Tradjenta | Linagliptin | 55 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 14 |
| Ezetimibe | Ezetimibe | 51 | 20 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 51 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 31 |
| Celecoxib | Celecoxib | 49 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 16 |
| Donepezil Hcl | Donepezil Hcl | 48 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 15 |
| Rybelsus | Semaglutide | 46 | 14 |
| Farxiga | Dapagliflozin Propanediol | 45 | 15 |
| Januvia | Sitagliptin Phosphate | 45 | 11 |
| Mirtazapine | Mirtazapine | 45 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 11 |
| Irbesartan | Irbesartan | 41 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Lorazepam | Lorazepam | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 21 |
| Nitroglycerin | Nitroglycerin | 39 | 26 |
| Vascepa | Icosapent Ethyl | 39 | 11 |
| Alprazolam | Alprazolam | 38 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 38 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | 11 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 37 | 11 |
| Topiramate | Topiramate | 37 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 14 |
| Bupropion Xl | Bupropion Hcl | 35 | 14 |
| Finasteride | Finasteride | 35 | 15 |
| Ondansetron Odt | Ondansetron | 35 | 13 |
| Spironolactone | Spironolactone | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 31 |
| Naproxen | Naproxen | 33 | suppressed |
| Lidocaine | Lidocaine | 32 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 24 |
| Cephalexin | Cephalexin | 28 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | 11 |
| Estradiol | Estradiol | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | 15 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Ubrelvy | Ubrogepant | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | 11 |
| Azelastine Hcl | Azelastine Hcl | 26 | 14 |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Metronidazole | Metronidazole | 25 | 22 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | 13 |
| Bumetanide | Bumetanide | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 21 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 15 |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nystop | Nystatin | 18 | 13 |
| Atenolol | Atenolol | 17 | suppressed |
| Desloratadine | Desloratadine | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 14 |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Terconazole | Terconazole | 17 | 16 |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $748.62 · 42 records | Novo Nordisk Inc | ACCRUFER, AIRSUPRA, AREXVY, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, NURTEC ODT, Ohtuvayre, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOYXACT, Wegovy, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error